Management of immune cytopenias in patients with systemic lupus erythematosus - Old and new

Autoimmunity Reviews

Volumn 12, Issue 7, 2013, Pages 784-791

  Newman, Kam ^a   Owlia, Mohammad Bagher ^b   El Hemaidi, Ihab ^c   Akhtari, Mojtaba ^d  

^a JAMAICA HOSPITAL MEDICAL CENTER   (United States)

^b SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cytopenia; G CSF; Growth factors; Hematologic manifestation; SLE; Systemic lupus erythematosus

Indexed keywords

ALLOANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DANAZOL; ERYTHROPOIETIN; FIBRINOGEN RECEPTOR; FOLIC ACID; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; RITUXIMAB; THROMBOPOIETIN RECEPTOR; UNINDEXED DRUG;

ALOPECIA; ANEMIA; APLASTIC ANEMIA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLEEDING; BLOOD TRANSFUSION; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE PAIN; BRAIN PSEUDOTUMOR; CHOLESTATIC HEPATITIS; CHRONIC DISEASE; CYTOPENIA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG MEGADOSE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GUILLAIN BARRE SYNDROME; HEMOLYSIS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERANDROGENISM; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE CYTOPENIA; INFECTION; INFECTION RISK; INFUSION REACTION; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEUKOCYTOCLASTIC VASCULITIS; LEUKOPENIA; LIVER ADENOMA; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTOPENIA; MONOCYTOPENIA; MULTIPLE CYCLE TREATMENT; MYASTHENIA GRAVIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PLASMAPHERESIS; PREMATURE OVARIAN FAILURE; PURE RED CELL ANEMIA; RASH; REVIEW; SIDE EFFECT; SPLENECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THROMBOEMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL; VIRILIZATION; VOMITING; WEIGHT GAIN;

ANEMIA; HUMANS; LEUKOPENIA; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOPENIA; NEUTROPENIA; PANCYTOPENIA; THROMBOCYTOPENIA;

EID: 84877838218     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.02.001     Document Type: Review

References (99)

1. Hepburn A.L., Narat S., Mason J.C. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology 2010, 49:2243-2254.
2. Newman K., El-Hemaidi I., Akhtari M. Hematologic manifestations of systemic lupus erythematosus. Lupus: symptoms, treatment and potential complications 2012, 129-144. Nova Science Publishers, New York, NY. T. Devesa Marquez, D. Urgeiro Neto (Eds.).
3. Quintero O.L., Rojas-Villarraga A., Mantilla R.D., Anaya J.M. Autoimmune diseases in the intensive care unit. An update. Autoimmun Rev 2013, 12:380-395.
4. Shoenfeld Y., Ehrenfeld M. Hematologic manifestation. The clinical management of systemic lupus erythematosus 1996, Lippincott, Philadelphia. 2nd ed. P.H. Schur (Ed.).
5. Nossent J.C., Swaak A.J. Prevalence and significance of hematological abnormalities in patients with systemic lupus erythematosus. Q J Med 1991, 80:605.
6. Keeling D.M., Isenberg D.A. Haematological manifestations of systemic lupus erythematosus. Blood Rev 1993, 7:199.
7. Jeffries M., Hamadeh F., Aberle T., et al. Haemolytic anaemia in a multi-ethnic cohort of lupus patients: a clinical and serological perspective. Lupus 2008, 17:739.
8. Lambert J.E., Nydegger U.E. Geoepidemiology of autoimmune hemolytic anemia. Autoimmun Rev 2010, 9(5):A350-A354.
9. Gomard-Mennesson E., Ruivard M., Koenig M., Woods A., Magy N., Ninet J., Rousset J., Salles G., Broussolle C., Seve P. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus 2006, 15:223-231.
10. King K.E., Ness P.M. Treatment of autoimmune hemolytic anemia. Semin Hematol 2005, 42:131-136.
11. Abu-Shakra M., Shoenfeld Y. Azathioprine therapy for patients with systemic lupus erythematosus. Lupus 2001, 10:152-153.
12. Corley C.C., Lessner H.E., Laresen W.E. Azathioprine therapy of "autoimmune" diseases. Am J Med 1966, 41:404.
13. Pignon J.M., Poirson E., Rochant H. Danazol in autoimmune hemolytic anemia. Br J Haematol 1993, 83(2):343-345.
14. Letchumanan P., Thumboo J. Danazol in the treatment of systemic lupus erythematosus: a qualitative systematic review. Semin Arthritis Rheum 2011, 40:298-306.
15. Chan A.C., Sack K. Danazol therapy in autoimmune hemolytic anemia associated with systemic lupus erythematosus. J Rheumatol 1991, 18:280-282.
16. Levy Y., Sherer Y., Ahmed A., Langevitz P., George J., Fabbrizzi F., Terryberry J., Meissner M., Lorber M., Peter J.B., Shoenfeld Y. A study of 20 SLE patients with intravenous immunoglobulin-clinical and serologic response. Lupus 1999, 8:705-712.
17. Zandman-Goddard G., Levy Y., Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 2005, 29:219-228.
18. Baxley A., Akhtari M. Hematologic toxicities associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2011, 11(11):1663-1667.
19. Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R., Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002, 46(10):2673-2677.
20. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008, 141(12):149-169.
21. Anolik J.H., Barnard J., Cappione A., Pugh-Bernard A.E., Felgar R.E., Looney R.J., Sanz I. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004, 50(11):3580-3590.
22. Merrill J., Buyon J., Furie R., Latinis K., Gordon C., Hsieh H.J., Brunetta P. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011, 20(7):709-716.
23. Gottenberg J.-E., Guillevin L., Lambotte O., Combe B., Allanore Y., Cantagrel A., Larroche C., Soubrier M., Bouillet L., Dougados M., Fain O., Farge D., Kyndt X., Lortholary O., Masson C., Moura B., Remy P., Thomas T., Wendling D., Anaya J.-M., Sibilia J., Mariette X., for the club rheumatisms et inflammation (CRI) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005, 64:913-920.
24. Conti F., Perricone C., Ceccarelli F., Valesini G. Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: two sides of the same coin. Autoimmun Rev 2010, 9(11):716-720.
25. Tanaka Y., Yamamoto K., Takeuchi T., Nishimoto N., Miyasaka N., Sumida T., Shima Y., Takada K., Matsumoto I., Saito K., Koike T. A multicenter phase I/II trial of refractory systemic lupus erythematosus. Mod Rheumatol 2007, 17:191-197.
26. Leandro M.J., Cambridge G., Edwards J.C., Ehrenstein M.R., Isenberg D.A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005, 44:1542-1545.
27. Smith K.G.C., Jones R.B., Burns S.M., Jayne D.R.W. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis. Remission, relapse, and re-treatment. Arthritis Rheum 2006, 54(9):2970-2982.
28. Reynolds J.A., Toescu V., Yee C.S., Prabu A., Gordon C. Effects of rituximab on resistant SLE disease including lung involvement. Lupus 2009, 18:67-73.
29. Perrotta S., Locatelli F., La Manna A., Cennamo L., De Stefano P., Nobili B. Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002, 116:465-467.
30. Penalver F.J., Alvarez-Larran A., Diez-Martin J.L., Gallur L., Jarque I., Caballero D., Diaz-Mediavilla J., Bustelos R., Fernandez-Acenero M.J., Cabrera J.R. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol 2010, 89:1073-1080.
31. Dierickx D., Verhoef G., Van Hoof A., Mineur P., Roest A., Triffet A., Kentos A., Pierre P., Boulet D., Bries G., Le P.-Q., Janssens A., Delannoy A. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med 2009, 266(5):484-491.
32. Burton C., Kaczmarski R., Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003, 348(26):2690-2691.
33. Voog E., Morschhauser F., Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003, 348(26):2691-2694.
34. Alba P., Karim Y.M., Hunt B.J. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2003, 12:633-635.
35. Mak A., Mok C.C. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus 2005, 14:856-858.
36. Mok C.C. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systemic review. Scand J Rheumatol 2007, 36:329-337.
37. Howard J., Hoffbrand A.V., Prentice H.G., Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenic purpura. Br J Haematol 2002, 117:712-715.
38. Moyo V.M., Smith D., Brodsky I., Crilley P., Jones R.J., Brodsky R.A. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood 2002, 100:704-706.
39. Buetens O.W., Ness P.M. Red blood cell transfusion in autoimmune hemolytic anemia. Curr Opin Hematol 2003, 10:429-433.
40. Voulgarelis M., Kokori S.I., Ioannidis J.P., et al. Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin. Ann Rheumatol Dis 2000, 59:217.
41. Winkler A., Jackson R.W., Kay D.S., Mitchel E., Carmignani S., Sharp G.C. High-dose intravenous cyclophosphamide treatment of systemic lupus erythematosus-associated aplastic anemia. Arthritis Rheum 1988, 31(5):693-694.
42. Singh N.P., Prakash A., Garg D., Makhija A., Pathania A., Prakash N., Kubba S., Agarwal S.K. Aplastic anemia complicating systemic lupus erythematosus: successful management with cyclosporine. Rheumatol Int 2004, 24:40-42.
43. Brooks B.J., Broxmeyer H.E., Bryan C.F., Leech S.H. Serum inhibitor in systemic lupus erythematosus associated with aplastic anemia. Arch Intern Med 1984, 144:1474-1477.
44. Fitchen J.J., Cline M.J., Saxon A., Golde D.W. Serum inhibitors of hematopoiesis in a patient with aplastic anemia and systemic lupus erythematosus. Recovery after exchange plasmapheresis. Am J Med 1979, 66:537-542.
45. Habib G.S., Saliba W.R., Froom P. Pure red cell aplasia and lupus. Semin Arthritis Rheum 2002, 31:279-283.
46. Liu H., Ozaki K., Matsuzaki Y., Abe M., Kosaka M., Saito S. Suppression of haematopoiesis by IgG autoantibodies from patients with systemic lupus erythematosis (SLE). Clin Exp Immunol 1995, 100:480.
47. Hara A., Wada T., Kitajima S., Toyama T., Okumura T., Kitagawa K., Iwata Y., Sakai N., Furuichi K., Higuchi M., Kaneko S. Combined pure red cell aplasia and autoimmune hemolytic anemia in systemic lupus erythematosus with anti-erythropoietin autoantibodies. Am J Hematol 2008, 83:750.
48. Brooks B.J., Broxmeyer H.E., Bryan C.F., Leech S.H. Serum inhibitors in systemic lupus erythematosus associated with aplastic anemia. Arch Intern Med 1984, 144:1474.
49. Roffe C., Cahill M.R., Samanta A., Bricknell S., Durrant S.T. Aplastic anaemia in systemic lupus erythematosus: a cellular immune mechanism?. Br J Rheumatol 1991, 30:301.
50. Jimeno Sainz A., Blazquez Encinar J.C. Pure red cell aplasia as the first manifestation of systemic lupus erythematosus. Am J Med 2001, 11:78-79.
51. Chan A.Y.K., Li E.K., Tam L.S., Cheng G., Choi P.C.L. Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with oral danazol and steroid. Rheumatol Int 2005, 25:388-390.
52. Ilan Y., Naparstek Y. Pure red cell aplasia associated with systemic lupus erythematosus: remission after a single course of intravenous immunoglobulin. Acta Haematol 1993, 89:152-154.
53. Mouthon L., Guillevin L., Tellier Z. Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red cell aplasia. Autoimmun Rev 2005, 4(5):264-269.
54. Duarte-Salazar C., Cazarin-Barrientos J., Goyocochea-Robles M.V., Collazo-Jaloma J., Burgos-Vargas R. Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with cyclosporine A. Rheumatology 2000, 39:1155-1157.
55. Atzeni F., Sarzi-Puttini P., Capsoni F., Vulpio L., Carrabba M. Successful treatment of pure red cell aplasia in systemic lupus erythematosus with cyclosporine A. Clin Exp Rheumatol 2003, 21:759-762.
56. Arcasoy M.O., Chao N.J. T-cell-mediated pure red cell aplasia in systemic lupus erythematosus: response to cyclosporine A and mycophenolate mofetil. Am J Hematol 2005, 78:161-163.
57. Schulze-Koops H. Lymphopenia and autoimmune diseases. Arthritis Res Ther 2004, 6(4):178-180.
58. Martinez-Banos D., Crispin J.C., Lazo-Langner A., Sanchez-Guerrero J. Moderate and severe neutropenia in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2006, 45(8):994-998.
59. Akhtari M., Curtis B., Waller E.K. Autoimmune neutropenia in adults. Autoimmun Rev 2009, 9(1):62-66.
60. Utsinger P.D. Relationship of lymphocytotoxic antibodies to lymphopenia and parameters of disease activity in systemic lupus erythematosus. J Rheumatol 1976, 3:175-185.
61. Newman K.A., Akhtari M. Management of autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus. Autoimmun Rev 2011, 10:432-437.
62. Manger K., Kalden J.R., Manger B. Cyclosporine A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol 1996, 35:669-675.
63. Euler H.H., Harten P., Zeuner R.A., Schab U.M. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. J Rheumatol 1997, 24:2153-2157.
64. Hellmich B., Schnabel A., Gross W.L. Treatment of severe neutropenia due to Felty's syndrome or systemic lupus erythematosus with granulocyte colony-stimulating factor. Semin Arthritis Rheum 1999, 29:82-99.
65. Kuwana M., Kaburaki J., Okazaki Y., Miyazaki H., Ikeda Y. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology 2006, 45:851-854.
66. Lurie D.P., Kahaleh M.B. Pulse corticosteroid therapy for refractory thrombocytopenia in systemic lupus erythematosus. J Rheumatol 1982, 9:311-314.
67. Maier W.P., Gordon D.S., Howard R.F., Saleh M.N., Miller S.B., Lieberman J.D., Woodlee P.M. Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum 1990, 33(8):1233-1239.
68. ter Borg E.J., Kallenberg C.G.M. Treatment of severe thrombocytopenia in systemic lupus erythematosus with intravenous gamma globulin. Ann Rheum Dis 1992, 51:1149-1151.
69. Maeshima E., Kida Y., Goda M., Minammi Y. A case of systemic lupus erythematosus expressing intractable thrombocytopenia remedied effectively by intermittent and continuous administration of a small amount of immune globulin. Mod Rheumatol 2006, 16:239-242.
70. Roldan R., Roman J., Lopez D., Gonzalez J., Sanchez C., Martinez F. Treatment of hemolytic anemia and severe thrombocytopenia with high-dose methyl prednisolone and intravenous immunoglobulins in SLE. Scand J Rheumatol 1994, 23(4):218-219.
71. West S.G., Johnson S. Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 1988, 108:703-706.
72. Cervera H., Jara L.J., Pizarro S., Enkerlin H.L., Frnandez M., Medina F., Fraga A., Miranda J.M. Danazol for systemic lupus erythematosus with refractory autoimmune thrombocytopenia or Evans' syndrome. J Rheumatol 1995, 22:1867-1871.
73. Arnal C., Piette J.C., Leone J., Taillan B., Hachulla E., Roudot-Thoraval F., Papo T., Schaeffer A., Bierling P., Godeau B. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002, 29:75-83.
74. Avina-Zubieta J.A., Galindo-Rodriguez G., Robledo I., Vela-Ojeda J., Vadillo-Buenfil M., Rosas-Cabral A., Salazar-Exaire D. Long-term effectiveness of danazol corticosteroids and cytotoxic drugs in the treatment of hematologic manifestations of systemic lupus erythematosus. Lupus 2003, 12:52-57.
75. Akada K., Illei G.G., Boumpas D.T. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001, 10:154-161.
76. Boumpas D.T., Barez S., Klippel J.H., Balow J.E. Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 1990, 112:674-677.
77. Vasoo S., Thumboo J., Fong K.-Y. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus 2003, 12:630-632.
78. Sugiyama M., Ogasawara H., Kaneko H., Hishikawa T., Sekigawa I., Iida N., Hashimoto H., Hirose S. Effect of extremely low dose cyclosporine treatment on the thrombocytopenia in systemic lupus erythematosus. Lupus 1998, 7:53-56.
79. Quartuccio L., Sacco S., Franzolini N., Perin A., Ferraccioli G., De Vita S. Efficacy of cyclosporine-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus. Lupus 2006, 15:76-79.
80. Lindholm C., Borjesson-Asp K., Zendjanchi K., Sundqvist A.-C., Tarkowski A., Bokarewa M. Long-term clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008, 35:826-833.
81. Brah S., Laurent C., Raphaelle F., Bornet C., Mancini J., Schleinitz N., Jean R., Kaplanski G. Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey. Ann Hematol 2012, 91(2):279-285.
82. Goebel K.M., Gassel W.D., Goebell F.D. Evaluation of azathioprine in autoimmune thrombocytopenia and lupus erythematosus. Scand J Haematol 1973, 10:28.
83. Feinglass S., Deodhar A. Treatment of lupus-induced thrombocytopenia with recombinant human interleukin-11. Arthritis Rheum 2001, 44.
84. Matsuyama T., Kuwana M., Matsumoto M., Isonishi I., Inokuma S., Fujimura Y. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb Haemost 2009, 102(2):371-378.
85. Kremer Hovinga J.A., Meyer S.C. Current management of thrombotic thrombocytopenic purpura. Curr Opin Hematol 2008, 15:445-450.
86. Hundae A., Peskoe S., Grimsley E., Patel S. Rituximab therapy for refractory thrombotic thrombocytopenic purpura and autoimmune-mediated thrombocytopenia in systemic lupus erythematosus. South Med J 2008, 101(9):943-944.
87. Limal N., Sene D., Guichard I., Piette J.-C. Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Lupus 2008, 17:69-71.
88. Enami T., Suzuki T., Ito S., Yoshimi A., Sugihara M., Mamura M., Hayashi T., Goto D., Matsumoto I., Tsutsumi A., Sumida T. Successful treatment of refractory thrombotic thrombocytopenic purpura with cyclosporine and corticosteroids in a patient with systemic lupus erythematosus and antibodies to ADAMTS13. Intern Med 2007, 46:1033-1037.
89. Vaidya S., Abul-ezz S., Lipsmeyer E. Thrombotic thrombocytopenic purpura and systemic lupus erythematosus. Scand J Rheumatol 2001, 30(5):308-310.
90. Fox D.A., Faix J.D., Coblyn J., Fraser P., Smith B., Weinblatt M.E. Thrombotic thrombocytopenic purpura and systemic lupus erythematosus. Ann Rheum Dis 1986, 45:319-322.
91. Starck M., Abedinpour F., Dendorfer U., Wagner-Czekalla J., Pachmann M., Mann J.F., Nerl C. Acquired thrombotic thrombocytopenic purpura as the presenting symptom of systemic lupus erythematosus. Successful treatment with plasma exchange and immunosuppression-report of two cases. Eur J Haematol 2005, 75:436-440.
92. Vasoo S., Thumboo J., Fong K.-Y. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: disease activity and the use of cytotoxic drugs. Lupus 2002, 11:443-450.
93. Perez-Sanchez I., Anguita J., Pintado T. Use of cyclophosphamide in the treatment of thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus: report of two cases. Ann Hematol 1999, 78:285-287.
94. Rivero S.J., Alger M., Alarcon-Segovia D. Splenectomy for hemocytopenia in systemic lupus erythematosus. A controlled appraisal. Arch Intern Med 1979, 139:773-776.
95. Hall S., McCormick J.H., Greipp P.R., Michet C.J., McKenna C.H. Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus. Ann Intern Med 1985, 102:325-328.
96. Hakim A.J., Machin S.J., Isenberg D.A. Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: the response to splenectomy. Semin Arthritis Rheum 1998, 28:20-25.
97. You Y.N., Tefferi A., Nagorney D.M. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. Ann Surg 2004, 240:286-292.
98. Coon W.W. Splenectomy for cytopenias associated with systemic lupus erythematosus. Am J Surg 1988, 155(3):391-394.
99. Gruenberg J., Vanslyck E.J., Abraham J.P. Splenectomy in systemic lupus erythematosus. Am Surg 1986, 52(7):366-370.